Table 1.
Baseline characteristics (N = 97).
| Randomized to Intensive study arm a | 46 (47.4) |
| Male a | 56 (57.7) |
| Race a | |
| White | 35 (36.1) |
| Black | 47 (48.5) |
| Others | 15 (15.5) |
| Age (years) b | 56.7 (13.4) |
| Vintage (years) c | 3.0 (1.1, 4.7) |
| Cause of end stage kidney disease a | |
| Diabetes mellitus | 52 (53.6) |
| Hypertension | 28 (28.9) |
| Glomerulonephritis | 8 (8.3) |
| Other | 9 (9.3) |
| Comorbid conditions a | |
| Myocardial infarction | 4 (4.1) |
| Congestive heart failure | 12 (12.4) |
| Peripheral vascular disease | 8 (8.3) |
| Current or Former Smoking history | 45 (46.4) |
| Body mass index (kg/m 2 ) c | 26.2 (22.9, 30.2) |
| Interdialytic weight gain (kg) d | 2.7 (1.2) |
| Interdialytic weight gain (% of estimated dry weight) d | 3.5 (1.3) |
| Prescribed treatment time (hours) e | 3.8 (3.5, 4.0) |
| Ultrafiltration volume (L) e | 2.9 (2.3, 3.5) |
| Predialysis systolic blood pressure (mm Hg) d | 159.4 (9.2) |
| Predialysis diastolic blood pressure (mm Hg) d | 80.0 (11.6) |
| Number of antihypertensive medications taken d | 2.6 (1.3) |
| Patients who had antihypertensive medication held predialysis a | |
| 1 medication held | 14 (14.4) |
| 2 medications held | 2 (2.1) |
| Percent of patients receiving specific classes of antihypertensive medications | |
| Angiotensin converting enzyme inhibitor | 42 |
| Angiotensin receptor blocker | 18 |
| Beta-adrenergic blocking agent | 75 |
| Calcium channel blocker | 60 |
| Central alpha agonist | 19 |
a
n(%)
b
mean (standard deviation)
c
median (interquartile range)
d
mean (standard deviation) for the month prior to randomization
e
median (interquartile range) for the month prior to randomization